Introduction {#sec1}
============

*Staphylococcus aureus* has been considered as one of the pathogenic bacteria responsible for a wide variety of diseases. Such diseases range from slight skin infections to critical infections including septicemia ([@bib22]). After the introduction of methicillin in 1959, methicillin-resistant *S. aureus* (MRSA) has transpired as a significant hospital-associated pathogen ([@bib22]). The widespread of MRSA and its capability for escalating in hospitals and community settings represent a real threat that stands against infection control practices ([@bib22]). The epidemiology of MRSA differs noticeably worldwide even at regional levels ([@bib2]). In comparison with other African, southern and eastern Mediterranean countries, Egypt showed the highest rates of MRSA occurrence among *S. aureus* clinical isolates ([@bib1]). According to the Antibiotic Resistance Surveillance and Control in the Mediterranean Region, more than 50% of the *S. aureus* isolates, obtained from blood cultures in Egypt, during a three-year study period (2003--2005), were recognized to be methicillin-resistant ([@bib2]). Poor and problematic healthcare system in the majority of African countries, not excluding Egypt, inadequate financing, poor provision of properly trained healthcare professionals, poverty in infrastructure and occasional lack of adequate medications aggravate the problem, making the fight of these countries against this pathogen a real challenge ([@bib7]).

Fluoroquinolones have been recognized as promising and potent antibiotics which inhibit DNA gyrase and topoisomerase IV resulting in impeding the supercoiling of the DNA and causing bacterial death ([@bib12]). The classic fluoroquinolones possess a considerable antimicrobial activity against Gram-negative bacteria, but their potency against Gram-positive bacteria has been controverted ([@bib17]). Therefore, research in the field of fluoroquinolones was oriented towards potentiating the antimicrobial efficacy against Gram-positive cocci, anaerobes and fluoroquinolone-resistant strains by finding substituents with better binding affinity to target enzymes ([@bib14]). Consequently, a number of new agents have been developed, among which was zabofloxacin ([@bib12]). Zabofloxacin is a novel member in the family of fluoroquinolones ([@bib17]) with reported activity against methicillin-resistant coagulase-negative staphylococci, *Streptococcus pyogenes, Streptococcus pneumoniae* and *Enterococcus faecalis*. Its activity against these organisms is regarded to be superior to other fluoroquinolones as ciprofloxacin, moxifloxacin, and gemifloxacin ([@bib17]; [@bib11]). Zabofloxacin is slightly inferior in comparison with other fluoroquinolones against *Enterobacteriaceae* family. However, it is effective against the Gram-negative respiratory bacteria, such as *Haemophilus influenzae* and *Moraxella catarrhalis* ([@bib11]). Owing to the double mechanism of binding of zabofloxacin to the complex enzyme-DNA, the likelihood of the development of bacterial resistance is markedly diminished ([@bib11]).

The present study compared the *in vitro* activity of zabofloxacin with moxifloxacin, levofloxacin and ciprofloxacin against MRSA clinical isolates collected from hospitalized patients admitted to the Alexandria Main University hospital (AMUH); a tertiary hospital based in Alexandria, Egypt, where zabofloxacin has not been yet introduced. In addition, the *in vivo* protective activity of zabofloxacin and comparator fluoroquinolones against systemic infection caused by MRSA clinical isolate was evaluated using a mice model.

Experimental {#sec2}
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Materials and Methods {#sec3}
---------------------

**Test organisms and bacterial identification.** One hundred-sixteen clinical isolates of MRSA were collected from the routine laboratory of Alexandria Main University Hospital (AMUH) over a six-month period between January 2017 to July 2017. The clinical origins of these isolates were as follow: bronchoalveolar lavages (n = 66), blood (n = 19), urine (n = 16), pus (n = 11), and wound swabs (n = 4). As a quality control, a reference strain of methicillin-sensitive *S. aureus* (MSSA; ATCC 25923) and a strains of methicillin-resistant *S. aureus* (MRSA; ATCC 43300) strains were included in this study.

The specimens were cultured on Mannitol Salt Agar and identified by colony morphology, Gram stain, as well as, by biochemical characteristics, which were estimated by the commercial test system Dry Spot Staphytect Plus (Oxoid, UK). Methicillin resistance was confirmed by cefoxitin and oxacillin disc diffusion methods according to the Clinical and Laboratory Standards Institute guidelines ([@bib5]).

**Antibiotics.** Ciprofloxacin, CIP, (Amryia Pharm. Ind., Egypt), levofloxacin, LEV, (Sanofi-Aventis, Germany) and moxifloxacin, MOX, (Alcon, Belgium) were purchased from pharmaceutical markets. Zabofloxacin powder, ZAB, was provided by the courtesy of Dongwha Pharm. Co., Ltd. (Seoul, Korea).

**Laboratory animals.** Five-week-old male Swiss albino mice (body weight, 17--21 g) were purchased from Theodor Bilharz Research Institute, Giza, Egypt. All mouse experiments were performed in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee, Faculty of Pharmacy, Alexandria University (ACUC Project \# ACUC18/28). Mice were housed in animal rooms maintained at 23 ± 2°C with 50 ± 20% relative humidity.

**Antimicrobial susceptibility testing.** Minimum inhibitory concentrations (MICs) were determined by the microtiter broth dilution method according to the guidelines of [@bib4]. Microtiter plates containing 5.0 × 10^5^ CFU/ml were incubated with serial dilutions of each antibiotic in Mueller-Hinton broth (Oxoid, UK) at 35°C for 18 h, and the lowest concentration of the antibiotic that prevented visible growth was considered as the MIC.

**Time-kill analysis.** The time-kill studies were performed following CLSI M26-A guidelines ([@bib3]). Two isolates, one resistant and one susceptible to the four tested fluoroquinolones, named S13 and S15 respectively, were selected for this analysis. The bacterial cultures in Muller-Hinton broth (Oxoid, UK) were diluted to reach an approximate count of 10^5^ to 10^6^ CFU/ml and preincu bated for 2 h. Then, ZAB, MOX, LEV and CIP were added to the cultures at concentrations of 0.5, 1, 2, and 4 MIC. The bacterial count was determined after 0, 3, 6 and 24 h of incubation with the antibiotics tested by culturing the bacteria on Muller-Hinton agar (Oxoid) at 37°C for 18 h following serial dilution. The anti bio tic was considered as bactericidal at a concentration, which decreased the control count by 3 log CFU/ml (99.9%) at specified time intervals. The procedure was performed in triplicates and a graph of the log CFU/ml was then plotted against time with calculation of standard deviation.

**Quinolone resistance-determining region (QRDR) sequence analysis.** PCR was used to amplify the QRDRs of the *gyrA, parC* and *parE* genes using extracted genomic DNA of the strains tested as a template and the previously described primer pairs and cycling conditions ([@bib15]). To determine alterations in the DNA gyrase or topoisomerase IV, selected PCR products were purified using Zymo Research^TM^ DNA Purification Kit and then sequenced using a system from LGC Co. Ltd. (Germany).

**Determination of ED50.** To determine and to compare the *in vivo* efficacy of ZAB to other fluoroquinolones in systemic infection murine model, four groups of four mice were challenged intraperitoneally with 0.2 ml of bacterial suspension adjusted with 5% gastric mucin (Oxoid, UK) in 0.9% NaCl solution at a dose 100 times higher than the minimal lethal dose. The challenge inoculum was sufficient to kill 100% of the untreated control mice, which died within 48 h after infection. An aliquot of 0.2 ml of each of ZAB, MOX, LEV and CIP was administrated twice orally to mice at 1 h and 4 h post infection. Four dose levels were used: 0.63, 2.5, 10 and 40 mg/kg of body weight for each fluoroquinolone. Mortality was recorded for seven days and the effective dose needed to protect 50% of the mice (ED50) was calculated by the method of Miller and Tainter with modifications ([@bib19]) from the survival rates on day 7 post infection.

**Bacteriological and histopathological examinations.** Twenty-five mice were allocated into five treatment groups: ZAB, MOX, LEV, CIP and normal saline (control). The doses of the antibiotics were adjusted to 10 mg/kg of body weight and injected intraperitoneally into mice twice daily beginning 24 h after infection. Mice were sacrificed by cervical dislocation on day 3 (12 h after the fourth administration). For bacteriological count, the lungs (n = 4 for each group) were dissected under aseptic conditions, suspended in 0.9% NaCl solution and homogenized. Serial dilutions were performed and bacterial count in homogenized lung was determined. Lung tissue for histological examination (n = 2 for each group) was fixed in 10% buffered formalin then stained with hematoxylin-eosin. Histopathological evaluation was done by an investigator who was blinded to the sample origin.

Results {#sec4}
=======

***In vitro* activity.** The microtiter broth dilution MICs were determined for 116 MRSA clinical isolates (Table [I](#tblI){ref-type="table"}). The strains showed the highest percentage of susceptibility to zabofloxacin (61.2%) among the fluoro quinolones tested. Comparing the MIC~50~ and MIC~90~, ZAB showed the highest potency with values of 0.25 and 2 µg/ml, respectively. Moxifloxacin followed ZAB in activity (MIC~50~ 0.5 µg/ml, MIC~90~ 8 µg/ml), then LEV (MIC~50~ 4 µg/ml, MIC~90~ 16 µg/ml) and the least effective was CIP (MIC~50~ 8 µg/ml, MIC~90~ 64 µg/ml). The distribution of MICs values for the four fluoroquinolones are shown in Table [II](#tblII){ref-type="table"}. The lowest MIC range among the tested fluoroquinolones was displayed by ZAB (0.03 -- 4 µg/ml). A comparable range (0.06 -- 16 µg/ml) was obtained by MOX while old generation fluoroquinolones, LEV and CIP, had a much higher range (0.125 -- \>64 µg/ml). In the presence of omeprazole, an efflux pump inhibitor ([@bib23]), the ZAB MIC values of all tested isolates remained unaffected (data not shown).

###### 

*In vitro* activity of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin against 116 MRSA clinical isolates.

![](pjm-68-1-059-t001)

  Antimicrobial agent   MIC (μg/ml)      \% Susceptible   \% Intermediate   \% Resistant         
  --------------------- ---------------- ---------------- ----------------- -------------- ----- ------
  Zabofloxacin          0.03 -- 4        0.25             2                 61.2           0.9   37.9
  Moxifloxacin          0.06 -- 16       0.5              8                 50.9           8.6   40.5
  Levofloxacin          0.125 -- 64      4                16                46.5           0.9   52.6
  Ciprofloxacin         0.125 -- \> 64   8                64                42.3           1.7   56

MIC~50~ and MIC~90~, MICs (μg/ml) for 50% and 90% of isolates tested, respectively.

###### 

MIC distribution of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin determined by broth microdilution method for 116 MRSA isolates.

![](pjm-68-1-059-t002)

  Antimicrobial agent   MIC (μg/ml)                                                                 
  --------------------- ------------- ---- ---- ---- ---- ---- -------- ------- ---- ---- ---- ---- ------------------------------------
  Zabofloxacin          10            17   25   12   7    1    **32**   12      0    0    0    0    0
  Moxifloxacin          0             2    7    35   15   10   **11**   21      13   2    0    0    0
  Levofloxacin          0             0    10   33   11   0    1        **8**   22   29   0    2    0
  Ciprofloxacin         0             0    4    18   19   8    2        **4**   11   19   14   14   3^[a](#FNt3){ref-type="table-fn"}^

Bold figures indicate CLSI breakpoints applied for resistant isolates; zabofloxacin and moxifloxacin: 2 µg/ml, levofloxacin and ciprofloxacin: 4 μg/ml.

MIC for these isolates was greater than or equal to the indicated value.

The bactericidal activity of the fluoroquinolones tested against MRSA was compared by time-kill analysis. As illustrated in figure [1A--D](#fig1){ref-type="fig"}, ZAB and MOX showed a comparable rapid bactericidal activity with a decrease in the viable count by ≥ 3 log~10~ CFU/ml after 6 h of contact when tested at the concentrations of 2 and 4 MIC against the fluoroquinolone-resistant clinical strain S13 (Fig. [1A](#fig1){ref-type="fig"} and [1B](#fig1){ref-type="fig"}). Against the fluoroquinolone-sensitive strain, S15, complete killing was achieved at 6 h when ZAB was used at a concentration of 2 MIC and at a concentration of 4 MIC when MOX was used (Fig. [2A](#fig2){ref-type="fig"} and [2B](#fig2){ref-type="fig"}). Regrowth of both isolates was completely inhibited by ZAB. Older classes fluoroquinolones, LEV and CIP, exhibited an inferior pattern of bactericidal activity (Fig. [2A--D](#fig2){ref-type="fig"}).

![Bactericidal activities of (A) zabofloxacin, (B) moxifloxacin, (C) levofloxacin and (D) ciprofloxacin against fluoroquinolone-resistant MRSA clinical isolate S13. Blue line, 0.5 MIC; red line, 1 MIC; green line, 2 MIC; purple line, 4 MIC. Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 3).](pjm-68-1-059-g001){#fig1}

![Bactericidal activities of (A) zabofloxacin, (B) moxifloxacin, (C) levofloxacin and (D) ciprofloxacin against fluoroquinolone-sensitive MRSA clinical isolate S15. Blue line, 0.5 MIC; red line, 1 MIC; green line, 2 MIC; purple line, 4 MIC. Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 3).](pjm-68-1-059-g002){#fig2}

**Analysis of QRDRs in selected MRSA strains.** PCR amplification of QRDR sequences of the *gyrA, parC* and *parE* genes were performed for fluoroquinolone-resistant isolates. Seven isolates showing different resistance patterns were selected for sequencing analysis to detect mutations in DNA gyrase and topoisomerase IV as shown in Table [III](#tblIII){ref-type="table"}. The detected mutations revealed the following amino acid substitutions: Ser-84→Leu in GyrA, Ser-80→Phe in GrlA and Pro-451→Ser in GrlB. Clinical isolates displaying resistance to ZAB had three mutations in the QRDRs of the *gyrA, parC* and *parE* genes, while isolates resistant to other fluoroquinolones, but not to ZAB, displayed a single or double point mutations.

###### 

MICs of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin for selected 7 clinical MRSA isolates with detected mutations in QRDRs.

![](pjm-68-1-059-t003)

  Strain No.   MIC (μg/ml)   Detected Mutation in QRDRs                                                                                             
  ------------ ------------- ---------------------------- ---- ---- --------------------------------------- --------------------------------------- ----------------------------------------
  S37          4             8                            32   64   S84L^[b](#FNt5){ref-type="table-fn"}^   S80F^[c](#FNt6){ref-type="table-fn"}^   P451S^[d](#FNt7){ref-type="table-fn"}^
  S30          2             8                            16   64   S84L                                    S80F                                    P451S
  S5           2             4                            16   64   S84L                                    S80F                                    P451S
  S3           2             8                            32   64   S84L                                    S80F                                    P451S
  S11          0.125         0.25                         8    32   S84L                                    None                                    P451S
  S38          0.25          0.25                         8    16   None                                    S80F                                    None
  S22          0.03          0.25                         4    8    None                                    S80F                                    None

ZAB: zabofloxacin, MOX: moxifloxacin, LEV: levofloxacin and CIP: ciprofloxacin.

Serine → Leucine,

Serine → Phenylalanine,

Proline → Serine.

***In vivo* activity.** The protective efficacy of ZAB against systemic infection in mice was compared with those of MOX, LEV and CIP (Table [IV](#tblIV){ref-type="table"}). Zabofloxacin exerted the most potent protective activity (MIC: 0.06 µg/ml; ED50: 29.05 mg/kg) followed by MOX (MIC: 0.06 µg/ml; ED50: 38.69 mg/kg), while LEV and CIP required a dose of more than 40 mg/kg to elicit a protective activity against the systemic infection (Table [IV](#tblIV){ref-type="table"}). These *in vivo* results were in accordance with the *in vitro* MICs values.

###### 

*In vivo* activities of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin against mice infected with MRSA S19 clinical isolate.

![](pjm-68-1-059-t004)

  Microorganism inoculum (CFU/mouse)                       Antimicrobial agent^[a](#FNt8){ref-type="table-fn"}^   MIC (μg/ml)   Count in dissected lungs log~10~ (CFU/ml)^[b](#FNt9){ref-type="table-fn"}^   ED50^[c](#FNt10){ref-type="table-fn"}^ (mg/kg)
  -------------------------------------------------------- ------------------------------------------------------ ------------- ---------------------------------------------------------------------------- ------------------------------------------------
  Methicillin-resistant *S. aureus* clinical isolate S19   Zabofloxacin                                           0.06          3.66                                                                         29.05
  Moxifloxacin                                             0.06                                                   4.31          38.69                                                                        
  Levofloxacin                                             8                                                      4.01          \> 40.00                                                                     
  Ciprofloxacin                                            16                                                     4.24          \> 40.00                                                                     

Each antimicrobial agent was administrated twice orally at 1 and 4 h post infection.

Count in control group receiving saline was log~10~ 5.5 CFU/ml.

ED50: median effective dose needed to protect 50% of the mice.

The mice group treated with ZAB showed the lowest count in the dissected lungs (3.66 log~10~ CFU/ml), when compared to other tested fluoroquinolones or to the control receiving saline (Table [IV](#tblIV){ref-type="table"}). These results again agreed with the *in vitro* time-kill curve findings in which ZAB showed the highest bactericidal activity as compared to the fluoroquinolones under investigation (Fig. [1A--D](#fig1){ref-type="fig"} and Fig. [2A--D](#fig2){ref-type="fig"}).

The histopathological examination of lung tissue sections obtained from CIP-treated mice group showed obvious features of acute bronchopneumonia almost the same as those in the untreated control with marked congestion, oedema, inflammatory infiltration, necrosis with accumulation of necro-inflammatory exudate within the lumen of bronchioles (Fig. [3](#fig3){ref-type="fig"}). The lungs of ZAB-treated mice group revealed very mild congestion and inflammation with scarce inflammatory cells in the interstitial spaces. The mice group treated with MOX and LEV displayed moderate interstitial inflammation, moderate congestion and oedema (Fig. [3](#fig3){ref-type="fig"}). Figure [4](#fig4){ref-type="fig"} demonstrates a patent alveolus dissected from ZAB-treated mice group, showing clear alveolar spaces and normal vessels and bronchioles lined by a layer of pneumocytes. The degree of congestion, inflammation, oedema and necrosis was scored using a scoring system adapted from [@bib6] and summarized in Table [V](#tblV){ref-type="table"}. Mice groups infected with MRSA clinical isolate S19 and treated with ZAB at an adjusted dose of 20 mg/kg of body weight/day, displayed best scores with least detected congestion, inflammation, oedema and necrosis followed by MOX, then LEV and finally CIP, all administrated at same dose regimen.

![Lung tissue sections dissected from mice infected with MRSA clinical isolate and treated with (A) zabofloxacin showing very mild congestion (arrow) and inflammation with scarce inflammatory cells in the interstitial spaces; (B) moxifloxacin showing moderate congestion with ectatic vessels (arrow) and moderate interstitial inflammation; (C) levofloxacin showing moderate inflammation, congestion and oedema, with a dilated lymphatic vessel (arrow); and (D) ciprofloxacin showing bronchopneumonic changes with marked congestion, oedema, inflammatory infiltration and necrosis, with accumulation of necro-inflammatory exudate within the lumen of bronchioles (arrow) (H&E x400).](pjm-68-1-059-g003){#fig3}

![(A, × 100) cross section of lung tissue dissected from mice treated with zabofloxacin showing patent alveoli, (B, × 400) clear alveolar spaces and normal vessels, the bronchioles are lined by a layer of pneumocytes (arrow).](pjm-68-1-059-g004){#fig4}

###### 

Scoring of detected congestion, inflammation, oedema and necrosis in lung tissues of mice groups infected with MRSA clinical isolate S19 and treated with zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin at a dose of 20 mg/kg of body weight/day.

![](pjm-68-1-059-t005)

  Histological observation^[a](#FNt11){ref-type="table-fn"}^   (Score 0--3)                         
  ------------------------------------------------------------ -------------- ---------- ---------- --
  Congestion                                                   0 (40%)                              
  +1 (20%)                                                     +1 (60%)       +2 (80%)   +3 (60%)   
  +2 (40%)                                                     +2 (40%)       +1 (20%)   +1 (40%)   
  Inflammation                                                 0 (40%)                              
  +1 (20%)                                                     +1 (60%)       +2 (80%)   +3 (60%)   
  +2 (40%)                                                     +2 (40%)       +1 (20%)   +1 (40%)   
  Edema                                                        0 (40%)                              
  +1 (20%)                                                     +1 (60%)       +2 (80%)   +3 (60%)   
  +2 (40%)                                                     +2 (40%)       +1 (20%)   +1 (40%)   
  Necrosis                                                     0 (40%)                              
  +1 (20%)                                                     +1 (60%)       +2 (80%)   +3 (60%)   
  +2 (40%)                                                     +2 (40%)       +1 (20%)   +1 (40%)   

Randomly selected sections blindly scored with a score applied to review of a whole lung section, scored at X10 magnification.

ZAB: Zabofloxacin, MOX: moxifloxacin, LEV: levofloxacin and CIP: ciprofloxacin.

Discussion {#sec5}
==========

Zabofloxacin is a novel fluoroquinolone recently appro ved and launched in South Korea ([@bib12]) with reported potent *in vitro* and *in vivo* activities against pathogens responsible for respiratory tract and uncomplicated skin infections such as *S. pneumoniae, H. influenzae, M. catarrhalis* and *S. aureus* ([@bib14]; [@bib17]). This fluoroquinolone targets DNA gyrase and topoisomerase IV, and due to its double mechanism of binding to the DNA-enzyme complex, mutations in both proteins are required for the development of high-level of resistance ([@bib16]). This agent has not been yet introduced to Egyptian healthcare facilities, including AMUH, a tertiary hospital with a heavy patient turnover and a significantly high prevalence rate (71%) of MRSA emerging as a nosocomial pathogen in its different departments ([@bib20]). Therefore, the present study was designed to evaluate and to compare the *in vitro* and *in vivo* activity of ZAB against MRSA clinical isolates to older fluoroquinolones available on the Egyptian market.

The MIC results showed that ZAB was 4, 8 and 32-fold more active than MOX, LEV and CIP, respectively (Tables I and II). Among the 116 tested MRSA isolates, 61.2% showed susceptibility to ZAB, the highest rate obtained among comparators. The MIC~50~ and MIC~90~ of ZAB were 0.25 and 2 µg/ml, respectively. These values were lower than that reported by [@bib14] and [@bib17] for MRSA isolates; probably due to lack of exposure of Egyptian isolates to this new antibiotic. In addition, ZAB exhibited a rapid bactericidal activity with a decrease in the viable count by ≥ 3 log~10~ CFU/ml after 6 h of contact when tested against a fluoroquinolone-resistant isolate and complete killing when tested against a fluoroquinolone-sensitive strain with inhibition of regrowth in both cases (Fig. [1A--D](#fig1){ref-type="fig"} and [2A--D](#fig2){ref-type="fig"}). Similar rapid bactericidal activity was reported by [@bib18], when ZAB was tested against clinical isolates of *S. pneumoniae*.

In *S. aureus*, topoisomerase IV and the A subunit of the DNA gyrase are the primary targets for quinolones ([@bib21]; [@bib11]; [@bib8]); consequently, the *gyrA, parC* and *parE* genes were screened for mutations in seven isolates showing different patterns of quinolone resistance. Isolates displaying resistance to ZAB (MIC: 2--4 µg/ml) were found to have their amino acids altered in positions: Ser84 in GyrA, Ser80 in ParC and Pro451 in ParE. Mutations at Ser84 in GyrA, Ser80 in ParC ([@bib24]) and Pro451 in ParE ([@bib9]) were reported to be associated with a high-level of quinolone resistance in *S. aureus*. A single point mutation or double point mutation were not able to elicit a considerable increase in MIC values of ZAB (Table [III](#tblIII){ref-type="table"}). [@bib18] reported previously that multiple mutations are required to produce significant elevations in MIC values of ZAB against *S. pneumoniae* isolates. Dual targeting and high susceptibility are desirable features in ZAB underlying its importance as a possible candidate for the treatment of infections caused by MRSA. The association of efflux mechanism with elevated MICs values has been reported for CIP and MOX ([@bib10]) while ZAB was shown to be a poor efflux substrate ([@bib18]), similar finding was obtained in the present study suggesting that ZAB is a poor substrate for NorA efflux pump.

The *in vivo* studies demonstrated that ZAB possessed the most potent protective effect against systemic infection caused by a MRSA strain isolated from bronchoalveolar lavage (Table [IV](#tblIV){ref-type="table"}), similar findings being reported by [@bib14] and [@bib17]. The histopathological examination of lung specimens of mice infected with MRSA isolate and treated with ZAB displayed least congestion, inflammation, oedema and necrosis (Table [V](#tblV){ref-type="table"}; Fig. [3](#fig3){ref-type="fig"}); the examined alveoli displayed clear alveolar spaces and normal vessels (Fig. [4](#fig4){ref-type="fig"}).

In conclusion, ZAB, a new fluoroquinolone not yet introduced to the Egyptian market, was proved to possess high *in vitro* and *in vivo* potency encompassing its comparators and might be regarded as an effective treatment option for infections caused by MRSA. The clinical usefulness of ZAB needs further establishment and confirmation in studies with larger number of isolates. To our knowledge, this is the first study evaluating the *in vitro* and *in vivo* activities of ZAB against Egyptian MRSA clinical isolates.
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